Retatrutide, by Soma Pharmaceuticals , represents a promising development in metabolic management . This innovative compound combines incretin signaling function with GIP receptor agonist engagement, demonstrating impressive results in trial studies for weight loss . Researchers believe this treatment could offer a different pathway for patients fa